| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002413894 |
| P356 | DOI | 10.1007/S11060-012-0860-1 |
| P698 | PubMed publication ID | 22528789 |
| P2093 | author name string | Sachiko Yamada | |
| Hiroshi Kanno | |||
| Nobutaka Kawahara | |||
| P2860 | cites work | Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells | Q23918117 |
| The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis | Q23919945 | ||
| Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site | Q23922326 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis | Q28570309 | ||
| Cellular uptake of the tat protein from human immunodeficiency virus | Q29620627 | ||
| Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery | Q31577177 | ||
| Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study | Q33398291 | ||
| Protection against ischemic brain injury by protein therapeutics | Q34431022 | ||
| Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein | Q34556566 | ||
| Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery | Q35100895 | ||
| The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters | Q37278005 | ||
| Antennapedia homeobox peptide regulates neural morphogenesis | Q37419251 | ||
| Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation | Q39540070 | ||
| Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells | Q40401963 | ||
| Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. | Q41063629 | ||
| Intercellular trafficking and protein delivery by a herpesvirus structural protein | Q41133058 | ||
| Analysis of the p53 gene and its expression in human glioblastoma cells | Q41488834 | ||
| Screening the p53 status of human cell lines using a yeast functional assay | Q42815910 | ||
| A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. | Q43697222 | ||
| Translocation of branched-chain arginine peptides through cell membranes: flexibility in the spatial disposition of positive charges in membrane-permeable peptides | Q44031394 | ||
| Efficient growth inhibition of human osteosarcoma cells using a peptide derived from the MDM-2-binding site of p53. | Q45855758 | ||
| Gene therapy -- promises, problems and prospects | Q45883584 | ||
| Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation | Q46454374 | ||
| Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents. | Q48966114 | ||
| p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. | Q52534736 | ||
| Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells | Q64378245 | ||
| Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells | Q73212113 | ||
| Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | Q73400021 | ||
| Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration | Q77658726 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 7-14 | |
| P577 | publication date | 2012-04-18 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53. | |
| P478 | volume | 109 |
| Q53088541 | A recombinant trans-membrane protein hMnSOD-R9 inhibits the proliferation of cervical cancer cells in vitro. |
| Q47844364 | Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro |
| Q38796979 | Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain |
| Q48229575 | Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy. |
| Q33702044 | Protein therapy using MafA fused to a polyarginine transduction domain attenuates glucose levels of streptozotocin‑induced diabetic mice. |
| Q36544248 | Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors |
Search more.